encorafenib,cetuximab,nivolumab
eli lilly,merck,bms,pfizer
['nivolumab', 'encorafenib', 'nivo', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'triplet', 'cetuximab', 'bristol', 'pfizer']
 updates:
at the ongoing #asco 2022, / presented data from the phase i/ii study evaluating the triplet combination of encorafenib + cetuximab + nivolumab in mss mcrc patients. learn more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry